1026. Diagnosis of sequencial Candidemia with the use of NMR biosensor
Session: Poster Abstract Session: Diagnosis of Bloodstream / Cardiovascular Infections
Saturday, October 22, 2011
Room: Poster Hall B1
  • 1026.pdf (315.0 kB)
  • Background: There is an increase in the fungal infections. Among them, Candida spp. are the fourth most common cause of hospital acquired bloodstream infections. Mortality from candidemia is over 30%, and early diagnosis and specific therapy intervention are very important factors to achieve a desirable prognosis. Unfortunately, the results from blood culture system utilized for candidemia diagnosis usually takes more than 2 days to be available, and may take as long as 5-7 days.

    Methods: The Relaxation Magnetic Switch technology (MRSw) has been used to detect pathogens within the blood stream. This technology is providing highly sensitive and specific results within a few hours directly from whole blood. The MRSw technology has been adapted to identify Candida spp. within whole blood samples by the T2DxTM platform at T2 Biosystems, Inc. Direct detection of the fungus in whole blood is achieved by coupling a whole blood compatible DNA amplification and detection technology.

    Results: The use of the T2Dx system to identify Candida spp. in serial blood samples was studied in patients with Candida spp. infections. In the first patient, four positive sequential blood samples for C. krusei were identified with the T2Dx system. In the second patient, two positive sequential blood samples for C. albicans were identified with the T2Dx system. In the third patient with port-a-cath culture for C. parapsilosis, two positive sequential blood samples for C. parapsilosis were identified with the T2Dx system. The T2Dx results were in concordance with blood culture but the assay allows for diagnosis to a species level in two hours without sample preparation and purification.

    Conclusion: A rapid identification of the Candida spp. from whole blood in serial blood samples can be achieved by the T2Dx system. In this pilot study the method was accurate. The evaluation of samples is ongoing and the updated data will be presented. A rapid and accurate diagnosis could allow antifungal therapy to be initiated much earlier, ultimately having the potential to drastically decrease the morbidity and mortality associated with candidemia.

    Subject Category: D. Diagnostic microbiology

    Jeffrey Coleman, Ph. D.1, Athanasios Desalermos, M.D.1, Maged Muhammed, M.D.1, Lori Neely, Ph.D.2, Mark Audeh2, Amy Castonguay2, N. A. Phung2, T. Wang2, Tom Lowery, Ph. D.2 and Eleftherios Mylonakis, M.D., Ph. D.1, (1)Massachusetts General Hospital, Harvard Medical School, BOSTON, MA, (2)T2 Biosystems Inc., Lexington, MA


    J. Coleman, None

    A. Desalermos, None

    M. Muhammed, None

    L. Neely, None

    M. Audeh, None

    A. Castonguay, None

    N. A. Phung, None

    T. Wang, None

    T. Lowery, None

    E. Mylonakis, Astella: Grant Investigator and Research Contractor, Consulting fee and Research grant
    T2 Biosystems: Grant Investigator, Grant recipient

    Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.